findmyKOL
Clinical trialNCT02572453TerminatedPhase 2Interventional

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

SponsorNational Cancer Institute (NCI)Enrollment25Recurrent Anaplastic Large Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Mantle Cell LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory Anaplastic Large Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma+2 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Los Angeles County-Usc Medical Center

    Los Angeles, California, United States

  • Usc / Norris Comprehensive Cancer Center

    Los Angeles, California, United States

  • Usc Norris Oncology/hematology-Newport Beach

    Newport Beach, California, United States

  • Keck Medical Center of Usc Pasadena

    Pasadena, California, United States

  • University of Kentucky/markey Cancer Center

    Lexington, Kentucky, United States

  • Johns Hopkins University/sidney Kimmel Cancer Center

    Baltimore, Maryland, United States

  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • Nebraska Medicine-Bellevue

    Bellevue, Nebraska, United States

  • Nebraska Medicine-Village Pointe

    Omaha, Nebraska, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, United States

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, United States

  • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital

    New Brunswick, New Jersey, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, United States

  • University of Pittsburgh Cancer Institute (upci)

    Pittsburgh, Pennsylvania, United States

  • Parkland Memorial Hospital

    Dallas, Texas, United States

  • Ut Southwestern/simmons Cancer Center-Dallas

    Dallas, Texas, United States

  • Huntsman Cancer Institute/university of Utah

    Salt Lake City, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
4 Apr 2016
Primary completion
18 Mar 2021
Completion
18 Mar 2021
Last update posted
13 Sept 2022
Registered enrollment
25
Registry id
NCT02572453

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.